Navigation Links
AHIP Statement on New CBO Report Showing That Senate Legislation Will Cut Medicare Advantage Enrollment by 2.3 Million
Date:7/9/2008

WASHINGTON, July 9 /PRNewswire-USNewswire/ -- The Congressional Budget Office (CBO) estimates that Medicare legislation currently being considered in the U.S. Senate (H.R. 6331) would decrease enrollment in Medicare Advantage by about 2.3 million individuals over the next five years. Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP) issued the following statement:

"More than two million seniors across the country stand to lose their Medicare Advantage benefits if these cuts become law. This could have devastating impact on seniors who rely on the extra benefits and lower out-of-pocket costs these plans provide. While it is important that Congress address the physician payment issue, they shouldn't take away seniors' health care choices in the process."

The CBO report is available here: http://www.cbo.gov/ftpdocs/95xx/doc9550/hr6331GreggLtr.pdf.

America's Health Insurance Plans - Providing Health Benefits to More Than 200 Million Americans


'/>"/>
SOURCE America's Health Insurance Plans
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. American Legacy Foundation(R) Statement of Support for the Federal Trade Commission Reversal on Tar and Nicotine Yield Statements on Cigarettes
2. The ECNP consensus statement on bipolar depression
3. Blue Cross and Blue Shield Association Statement: Health Care America Now
4. Anthem Blue Cross Statement on Settlement Discussions with the California Department of Managed Health Care
5. Statement Regarding the Filing of Signatures to Put the Human Embryo Stem Cell Issue on the November Statewide Ballot
6. GO3 Statement Regarding Erroneous Coverage in Star Magazine
7. AAHSA Statement: Therapy Caps Ration Care
8. Statement by Christine James-Brown, President and CEO, Child Welfare League of America (CWLA) Re: Moratorium on Medicaid Regulations
9. Test For Life Shares Senator Burr Statement on National HIV Testing Day
10. National Headache Foundation Offers Statement, Experts on Appropriate Use of Medications for Migraine Treatment
11. Pelosi Statement on Strong Bipartisan Vote in the House for Medicare Improvements Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively ... it is not known to have significant interactions with antiretroviral therapy (ART). ... cholesterol levels and dampen inflammation in the bloodstream. , While lowering cholesterol and ...
(Date:4/24/2017)... ... 24, 2017 , ... Labs often perform the same operations ... operators and management to assess these processes with a critical eye—particularly in the ... , Created with the help of both internal and external process experts, ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each person ... author, Jerri Broglin, a survivor of great loss who gained insight on how to ... those searching for answers, as we are finding the answers that are so deep ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue ... Oral Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel ...
(Date:4/24/2017)... ... 24, 2017 , ... Anaconda BioMed, a pre-clinical stage medical ... treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna Medical ... towards regulatory and clinical phases. , "This is another important step for Anaconda ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... R.I. , April 20, 2017  CVS ... CVS), today unveiled a new store design to ... assortment of healthier food, health-focused products and expanded ... store to help customers discover new offerings. Together ... the next evolution of the customer experience at ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology: